Answers are grounded in this paper and cite their sources.
This analysis demonstrates improved vector production in gene therapy using stable producer cell lines, suggesting enhanced efficiency.
Watch the video or read the poster to learn:Why does consistent, large-scale vector production remain a challenge?How can stable producer lines help meet rising demand as we enter the era of gene therapy?About the speakerRoy Bin Liu Business Development Director, EurekaBio. Mr Liu graduated from the Hong Kong University of Science and Technology with a Masters degree in Biotechnology. He previously worked in Bio-techne and InvivoGen. Mr Liu joined Eureka Bio in 2016, and has extensive knowledge of the cell and gene therapy industry, and is experienced in business development, project management, process development, cGMP etc.
No takes yet. Share an insight, caveat, or question.
Roy Bin Liu (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: